Oncolytic adenovirus‑mediated mda‑7/IL‑24 expression suppresses osteosarcoma growth and enhances sensitivity to doxorubicin

Retraction in: /10.3892/mmr.2021.12476

  • Authors:
    • Zongming Liu
    • Libo Xu
    • Hongping Yuan
    • Yang Zhang
    • Xiaona Zhang
    • Dongxu Zhao
  • View Affiliations

  • Published online on: August 5, 2015     https://doi.org/10.3892/mmr.2015.4180
  • Pages: 6358-6364
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma (OS) is a malignant disease with a high mortality rate and poor response to current chemotherapy. Melanoma differentiation associated gene‑7 (Mda7)/interleukin (IL)‑24 has been demonstrated to suppress the growth of OS. However, the expression level of Mda7/IL‑24 mediated by the current adenoviral vector is limited for effective clinical treatment of OS. In order to solve this issue, an oncolytic adenovirus was employed to express IL‑24 (OA‑IL‑24) in OS cells. Quantitative polymerase chain reaction, immunoblot and ELISA assays verified that OA‑IL‑24 expressed IL‑24 at a higher level than the replication‑deficient adenoviral vector, Ad‑IL24. OA‑IL‑24 infection led to decreased cell viability and increased apoptosis of OS cells, compared with Ad‑IL‑24. Animal studies further confirmed the increased anti‑tumor activity of OA‑IL‑24. Notably, OA‑IL‑24 was also found to sensitize OS cells to doxorubicin. OA‑IL‑24‑induced multiple drug resistance reversion was associated with reduced expression of Pgp and BCRP1, as well as minimized autophagy. Furthermore, restoring Pgp and BCRP1 expression as well as autophagy, was able to rescue the effect of IL‑24 on the cytotoxicity of doxorubicin to OS. In conclusion, a method for inducing a high expression of IL‑24 in OS was provided. In addition, IL‑24 was demonstrated to increase the sensitivity of OS to doxorubicin.
View Figures
View References

Related Articles

Journal Cover

October-2015
Volume 12 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Z, Xu L, Yuan H, Zhang Y, Zhang X and Zhao D: Oncolytic adenovirus‑mediated mda‑7/IL‑24 expression suppresses osteosarcoma growth and enhances sensitivity to doxorubicin Retraction in /10.3892/mmr.2021.12476. Mol Med Rep 12: 6358-6364, 2015
APA
Liu, Z., Xu, L., Yuan, H., Zhang, Y., Zhang, X., & Zhao, D. (2015). Oncolytic adenovirus‑mediated mda‑7/IL‑24 expression suppresses osteosarcoma growth and enhances sensitivity to doxorubicin Retraction in /10.3892/mmr.2021.12476. Molecular Medicine Reports, 12, 6358-6364. https://doi.org/10.3892/mmr.2015.4180
MLA
Liu, Z., Xu, L., Yuan, H., Zhang, Y., Zhang, X., Zhao, D."Oncolytic adenovirus‑mediated mda‑7/IL‑24 expression suppresses osteosarcoma growth and enhances sensitivity to doxorubicin Retraction in /10.3892/mmr.2021.12476". Molecular Medicine Reports 12.4 (2015): 6358-6364.
Chicago
Liu, Z., Xu, L., Yuan, H., Zhang, Y., Zhang, X., Zhao, D."Oncolytic adenovirus‑mediated mda‑7/IL‑24 expression suppresses osteosarcoma growth and enhances sensitivity to doxorubicin Retraction in /10.3892/mmr.2021.12476". Molecular Medicine Reports 12, no. 4 (2015): 6358-6364. https://doi.org/10.3892/mmr.2015.4180